Metropolis Healthcare Ltd
METROPOLISMetropolis Healthcare Ltd
METROPOLIS
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 73.26 | 9.87 | 0.19% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast from 14 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Metropolis Healthcare is a medical laboratory operator
Investor Presentation
View olderPeers
Compare with peersApollo Hospitals Enterprise Ltd
Max Healthcare Institute Ltd
Fortis Healthcare Ltd
Global Health Ltd
Narayana Hrudayalaya Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 493.95 | 570.31 | 654.93 | 769.39 | 864.98 | 1,010.04 | 1,261.96 | 1,163.43 | 1,216.83 | 1,295.69 | ||||||||||
Raw Materials | 124.59 | 135.10 | 145.90 | 173.51 | 204.14 | 252.16 | 276.02 | 253.26 | 242.57 | 971.74 | ||||||||||
| Power & Fuel Cost | 8.06 | 9.12 | 9.99 | 11.00 | 12.49 | 12.00 | 14.73 | 14.43 | 16.20 | |||||||||||
| Employee Cost | 108.18 | 127.70 | 147.37 | 176.21 | 190.16 | 198.64 | 233.17 | 252.73 | 275.78 | |||||||||||
| Selling & Administrative Expenses | 87.03 | 101.29 | 90.92 | 106.87 | 165.77 | 185.28 | 311.76 | 289.77 | 307.81 | |||||||||||
| Operating & Other expenses | 20.32 | 18.01 | 74.51 | 91.07 | 71.76 | 60.12 | 44.68 | 44.67 | 77.42 | |||||||||||
EBITDA | 145.77 | 179.09 | 186.24 | 210.73 | 220.66 | 301.84 | 381.60 | 308.57 | 297.05 | 323.95 | ||||||||||
| Depreciation/Amortization | 16.64 | 17.23 | 19.02 | 20.07 | 39.27 | 45.94 | 63.22 | 89.22 | 94.47 | 103.77 | ||||||||||
| PBIT | 129.13 | 161.86 | 167.22 | 190.66 | 181.39 | 255.90 | 318.38 | 219.35 | 202.58 | 220.18 | ||||||||||
| Interest & Other Items | 1.60 | 1.94 | 3.54 | 4.12 | 12.65 | 11.56 | 25.02 | 31.85 | 27.89 | 20.32 | ||||||||||
| PBT | 127.53 | 159.92 | 163.68 | 186.54 | 168.74 | 244.34 | 293.36 | 187.50 | 174.69 | 199.86 | ||||||||||
| Taxes & Other Items | 50.73 | 58.26 | 59.45 | 66.40 | 41.41 | 61.22 | 79.16 | 44.62 | 46.87 | 51.83 | ||||||||||
| Net Income | 76.80 | 101.66 | 104.23 | 120.14 | 127.33 | 183.12 | 214.20 | 142.88 | 127.82 | 148.03 | ||||||||||
| EPS | 15.22 | 20.48 | 21.00 | 24.07 | 25.26 | 36.00 | 41.88 | 27.91 | 24.96 | 28.90 | ||||||||||
| DPS | 15.46 | 10.07 | 0.00 | 13.26 | 8.00 | 8.00 | 8.00 | 8.00 | 4.00 | 4.00 | ||||||||||
| Payout ratio | 1.02 | 0.49 | 0.00 | 0.55 | 0.32 | 0.22 | 0.19 | 0.29 | 0.16 | 0.14 |
Company Updates
Peers & Comparison
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Metropolis Healthcare Ltd | 84.85 | 9.87 | 0.19% |
| Apollo Hospitals Enterprise Ltd | 118.75 | 14.58 | 0.22% |
| Max Healthcare Institute Ltd | 99.20 | 12.48 | 0.14% |
| Fortis Healthcare Ltd | 78.25 | 5.48 | 0.16% |
Price Comparison
Compare METROPOLIS with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Metropolis Healthcare Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Tata Business Cycle Fund-Direct Plan-Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4531% | Percentage of the fund’s portfolio invested in the stock 1.71% | Change in the portfolio weight of the stock over the last 3 months 0.47% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 54/99 (+3) |
Templeton India Value Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3513% | Percentage of the fund’s portfolio invested in the stock 1.71% | Change in the portfolio weight of the stock over the last 3 months -0.46% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 29/54 (-13) |
UTI Small Cap Fund - Direct Growth Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3227% | Percentage of the fund’s portfolio invested in the stock 0.80% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 70/99 (-29) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
METROPOLIS has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.18%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.82 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateNov 17, 2023
Dividend/Share
₹4.00
Ex DateEx Date
Nov 17, 2023
Cash Dividend
Ex DateEx DateFeb 23, 2023
Dividend/Share
₹8.00
Ex DateEx Date
Feb 23, 2023
Cash Dividend
Ex DateEx DateFeb 21, 2022
Dividend/Share
₹8.00
Ex DateEx Date
Feb 21, 2022
Cash Dividend
Ex DateEx DateFeb 17, 2021
Dividend/Share
₹8.00
Ex DateEx Date
Feb 17, 2021
Cash Dividend
Ex DateEx DateFeb 13, 2020
Dividend/Share
₹8.00
Ex DateEx Date
Feb 13, 2020
Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live
Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live
Metropolis Healthcare is a diagnostics company, with presence in 23 states & 601 towns. Internationally, the company has presence in South Asia, Africa, and the Middle East. It offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company has a network of over 199 labs, 4,150 collection centres and over 10,000 touch points. The company's consolidated net profit increased 7.9% to Rs 36.1 crore in Q1 FY25 as compared with Rs 33.5 crore in Q1 FY24. Revenue from operations increased 17.7% to Rs 331 crore in Q1 FY25, compared to Rs 282.5 crore in Q1 FY24. The scrip rose 0.70% to settle at Rs 2,273.05 on Friday, 11 October 2024. Powered by Capital Market - Live
Revenue growth was driven by patient volume growth, test volume growth and change in product mix coupled with realization benefits. B2C revenues jumped around 20% YoY during the period under review, on account of industry-leading testing capabilities and strong brand appeal among end consumers. The company has been able to deliver strong results in Q2FY25 driven by a combination of increased volumes, product mix change and realizations benefits. Continued momentum from its Truhealth packages, along with successful upselling of bundled packages, led to higher test per patient, contributing to overall revenue growth. The company has added 6 labs and 120 centers in Q2FY25 and increased the presence to a total of approximately 700 towns in Q2FY25 compared to approximately 650 towns in FY24. Margins for Q2FY25 have expanded on a sequential basis in line with commentary provided earlier. The Company continues to see a gradual uptick in margins on account of operating leverage, cost optimization and growing contribution from its ongoing network expansion, it added. The company said that it is debt free & having cash reserves of approximately Rs 180 crore as on 30 September 2024. Metropolis Healthcare is a diagnostics company, with presence in 23 states & 601 towns. Internationally, the company has presence in South Asia, Africa, and the Middle East. It offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company has a network of over 199 labs, 4,150 collection centres and over 10,000 touch points. The scrip fell 0.87% to settle at Rs 2,215 on the BSE.Powered by Capital Market - Live
Net profit of Metropolis Healthcare rose 31.77% to Rs 37.95 crore in the quarter ended June 2024 as against Rs 28.80 crore during the previous quarter ended June 2023. Sales rose 13.09% to Rs 313.36 crore in the quarter ended June 2024 as against Rs 277.09 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales313.36277.09 13 OPM %25.1522.71 - PBDT76.6260.01 28 PBT51.0839.19 30 NP37.9528.80 32 Powered by Capital Market - Live
Metropolis Healthcare will hold a meeting of the Board of Directors of the Company on 10 August 2024.Powered by Capital Market - Live
Metropolis Healthcare announced that the 24th Annual General Meeting (AGM) of the company will be held on 21 August 2024.Powered by Capital Market - Live
Metropolis Healthcare has allotted 12,823 equity shares under the MHL- Restrictive Stock Unit Plan, 2020.Powered by Capital Market - Live
Metropolis Healthcare revenue climbs 13% YoY Q1
Indians More Willing to Spend on Health Post-Covid; Demand for Wellness Packages Up: Metropolis Healthcare CEO - News18
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 9.6%, vs industry avg of 10.02%
Decreasing Market Share
Over the last 5 years, market share decreased from 2.1% to 1.97%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 1.25%, vs industry avg of 42.9%